University of Pittsburgh researchers have developed a novel formulation for the simultaneous delivery of Verteporfin and glutaminase inhibitors to the lungs and pulmonary blood vessels. Verteporfin, an FDA-approved drug for macular degeneration, inhibits the Yap/Taz pathway involved in tissue remodeling and extracellular matrix stiffening, which leads to pulmonary hypertension. Glutaminase inhibitors, such as C968 and CB-839, target the glutaminolysis pathway, a major energy source during pulmonary hypertension. This innovative approach aims to reduce pulmonary hypertension by blocking the Yap/Taz-GLS1 axis through controlled delivery of these drugs using poly(lactic-co-glycolic) acid (PLGA) particles.